Company news

Astellas Pharma Inc. news in 2025

Astellas Pharma Inc.'s news releases, calls and decks from 2025, newest first.

View company

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

December 17, 2025

Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines

December 11, 2025

Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium

December 10, 2025

Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting

December 5, 2025

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

November 21, 2025

Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)

October 23, 2025

Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study

October 22, 2025

PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer

October 21, 2025

IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety

October 19, 2025

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

October 18, 2025

Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society

October 13, 2025

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

October 13, 2025

Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting

October 8, 2025

Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025

October 1, 2025

Astellas Announces Top Management Personnel Change

September 29, 2025

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

August 12, 2025

Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"

July 16, 2025

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

June 13, 2025

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2

May 29, 2025

Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers

May 28, 2025

Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

May 22, 2025

Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio

May 21, 2025

Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting

May 19, 2025

Notice of Nominees for Directors

May 7, 2025

Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses

May 1, 2025

U.S. FDA Approves Expanded Label for Astellas IZERVAY for Geographic Atrophy

February 13, 2025

Astellas Pharma Inc. - Recording of Extraordinary Losses in Non-consolidated Financial Results

February 6, 2025

Astellas Pharma - China's National Medical Products Administration Approves VYLOY for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

January 6, 2025

Calls in 2025

Decks in 2025